XFOR earnings analysis
What we found in XFOR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
X4 Pharmaceuticals reported a notable revenue decline in Q4 2026, with total revenue decreasing by $26.1 million to $2.7 million compared to the same period last year. The operating loss widened to $20.3 million partly due to decreased revenues and adjusted expenses, despite a significant EPS improvement from -0.35 to -0.22 vs consensus. The company remains focused on progressing its clinical trial for mavorixafor while addressing operational challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surprises on the Upside
- Actual revenue of $2.7M exceeded estimates of $1.7M by 50%.
- Significant EPS Improvement
- Reported EPS of -$0.22 improved from est. -$0.35, a surprise of 37.14%.
- Cost Reductions in Operations
- Total operating expenses fell by $15.2 million to $23.0 million from $38.2 million year-over-year.
- Increased Product Revenue
- Net product sales increased to $2.5 million, up from $0.9 million in the prior year.
- Cash Position Solidified
- Cash and equivalents stood at $217.5 million, up from $41.0 million year-over-year.
- Investment Income Growth
- Interest income increased to $2.1 million from $1.0 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Loss Validation
- Total revenue significantly dropped from $28.8 million in Q4 2025 to $2.7 million.
- Operating Loss Increase
- The operating loss widened by $10.9 million, reaching $20.3 million compared to $9.4 million previously.
- Continued Cash Burn
- Operating cash flow used reached $19.6 million in Q1 2026, worsening from $12.4 million year-over-year.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.22
What they said about what is next.
Management anticipates continued funding challenges if additional capital is not raised.
The filing reads worse than the one before it.
What came before.
- 10-K · March 17, 2026
- X4 Pharmaceuticals is a small biopharma focused on mavorixafor (XOLREMDI), its only approved product for WHIM syndrome, and on completing the global Phase 3 4WARD trial in chronic neutropenia (target enrollment 176…
- 10-Q · November 5, 2025
- X4 reported Q3 2025 revenue of $1.8 million (vs. $0.6M in Q3 2024), driven by product sales of $1.566 million, while reducing R&D and SG&A. Despite year-over-year improvement in revenue and a narrower net loss, the…
- 10-Q · August 8, 2025
- X4 reported Q2 revenue of $1.973 million, up from $563 thousand in Q2 2024 but sharply down versus Q1 2025 (Q1 revenue implied $28.807 million), resulting in strong gross margins (83.5%) but a large operating loss of…
- 10-Q · May 1, 2025
- X4 reported first-quarter revenue of $28.8M driven by $27.9M of license/other revenue and $0.9M of product sales, producing GAAP net income of $0.3M, or $0.04 per share, versus a loss of $(51.8)M ( $(7.77) per share) in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XFOR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever